MedPath

Venlafaxine

Generic Name
Venlafaxine
Brand Names
Effexor
Drug Type
Small Molecule
Chemical Formula
C17H27NO2
CAS Number
93413-69-5
Unique Ingredient Identifier
GRZ5RCB1QG

Overview

Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD). Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches, for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).

Background

Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD). Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches, for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).

Indication

Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.

Associated Conditions

  • Generalized Anxiety Disorder
  • Major Depressive Disorder (MDD)
  • Migraine
  • Neuropathic Pain
  • Panic Disorder
  • Social Anxiety Disorder (SAD)
  • Vasomotor Symptoms Associated With Menopause

FDA Approved Products

venlafaxine
Manufacturer:Rising Pharma Holdings, Inc.
Route:ORAL
Strength:25 mg in 1 1
Approved: 2023/08/21
NDC:57237-172
Venlafaxine Hydrochloride
Manufacturer:Rebel Distributors Corp.
Route:ORAL
Strength:37.5 mg in 1 1
Approved: 2007/01/30
NDC:21695-716
venlafaxine
Manufacturer:Rising Pharma Holdings, Inc.
Route:ORAL
Strength:37.5 mg in 1 1
Approved: 2023/08/21
NDC:57237-173
Venlafaxine
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:75 mg in 1 1
Approved: 2021/11/17
NDC:70518-3269
Venlafaxine Hydrochloride
Manufacturer:MedVantx, Inc.
Route:ORAL
Strength:75 mg in 1 1
Approved: 2013/02/25
NDC:66116-447

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath